Practo: Building Trust Infrastructure in India’s Fragmented Doctor-Discovery Market
Industry & Competitive Context
Online doctor discovery in India grew out of a supply problem. An Outlook Business report on the early online-booking category noted that India had roughly one physician per 1,700 patients, well below the WHO benchmark of one per 1,000. In a market with scarce doctors and little visible quality information, a platform that could show who is available and credible had an obvious role.
The competitive set spans several adjacent models. Doctor-discovery and booking apps such as Practo and Lybrate sit alongside online pharmacy and consultation platforms such as 1mg, a Tata subsidiary offering lab bookings and consultations, and AI-led teleconsultation players such as MFine. Hospital-backed platforms such as Apollo 24/7 are also named in industry coverage. The category’s boundaries blur because each player adds pharmacy, diagnostics and consultations to its core.
Brand Situation Prior to the Consumer Platform
Practo’s consumer brand sits on top of a business that started on the provider side. It was founded in 2008 by Shashank ND and Abhinav Lal while they were studying at NIT Surathkal, and began as a practice-management software provider. The consumer-facing doctor discovery and appointment platform followed in March 2013.
The early commercial logic was documented by Outlook Business. Practo search was free for patients, while the Practo Ray software generated the revenue. The same report notes that Practo was present in 35 Indian cities and held the top market-share position for Ray in Singapore and Manila.
Funding followed the consumer launch, though not immediately. Practo took almost two years to raise venture capital. Sequoia invested $3.9 million in 2012, followed by a $30 million Series B and a $90 million Series C led by Tencent in 2015. A $55 million Series D in January 2017 reportedly valued the company at $600–650 million.
Inorganic moves are also documented. Commentary cites acquisitions or acqui-hires including Enlightiks, whose roughly 50 engineers joined Practo, plus Instahealth, Qikwell, Genii and FitHo.
Strategic Objective
Practo has never published a single campaign objective, but its stated priorities have shifted in a documented sequence.
The first objective was breadth. The 2015–2017 funding era coincided with the consolidation moves above and the expansion of the doctor network.
By 2024 the objective was sustainable economics. CEO Shashank ND said in a company statement carried by PTI that the goal had always been improving healthcare outcomes while building a sustainable business. By its FY25 annual letter, the company named three pillars: better outcomes through AI, scaling impact globally, and sustained profitability with growth. The stated timeline for growth targets has not always matched results. A Business Standard headline reported the CEO expecting roughly 100% year-on-year growth to about Rs 400 crore revenue in FY24. The company’s reported FY24 revenue was Rs 240 crore. The timing of the earlier statement is not given in the source, but the gap shows how far the strategy moved from growth-first to profit-first.
On listing, co-founder Abhinav Lal told Mint in October 2023 that Practo was 12–18 months from going public. Public-market plans have since been reported again in a different form (see Section 7).
Campaign Architecture & Execution
Practo’s execution is best read as a layered platform in which each layer supports the others.
Provider software layer. Practo Ray and the hospital system Insta anchor the provider relationship. The company reported that Insta is used by over 1,500 healthcare centres worldwide, holds a 15% share in the UAE, and has a 98% customer retention rate. This is a company-stated figure for the B2B product and not for the consumer marketplace.
Consumer discovery and booking layer. This is the layer most users know, covering search, doctor profiles and appointment booking. In 2020 Practo and the Telemedicine Society of India published a report finding that online-consultation users tripled between March and November 2020 while in-person appointments fell 32%. Practo also launched online consultations in 15 Indian languages and a corporate vaccination programme, “Corporate Suraksha.”
Trust and quality layer. This is the most strategically distinctive addition. Practo introduced the “excellence score” in FY24 and Practo Assured, a curated network of verified hospitals and clinics across 15 specialties, built around a proprietary Hospital Excellence Rating inspired by the NABH framework. The company’s FY25 communications say it audited over 1,000 healthcare establishments and processed more than 4 crore clinical data points.
Geographic layer. In FY24 the company reported that revenue in tier II and III markets grew 50%, against 20% in tier I. It then expanded abroad, entering the UAE and then launching in the US, where it reports over 300,000 monthly active users, with traffic up nearly six-fold since launch, and, per Entrackr, a $75 million GMV run-rate.
Positioning & Consumer Insight
Practo’s public language shows a move from “find a doctor” to “navigate care.” Inc42 describes the company as operating a care-navigation platform that lets patients discover, book and complete their healthcare journeys. The CEO, speaking about the US launch, said the platform is built to solve for trust, depth, and care navigation.
The documented insight behind this is trust. Practo reported that 1,500 hours of consumer research in FY24 highlighted the importance of trust in choosing healthcare providers and the potential role of AI in those interactions. Practo Assured was also introduced alongside a survey of 300 participants on what drives hospital and clinic selection. The full survey findings and methodology are not publicly detailed in the sources reviewed.
Strategically, this is a different bet from simple listing. A directory competes on how many doctors it lists. A trust layer competes on how reliably it narrows the choice. This reading is analytical, but it follows from Practo’s own framing of verified networks, scores and audits.
Media & Channel Strategy
The documented channels are the product surfaces themselves, namely the web and mobile apps, plus enterprise relationships such as the corporate vaccination programme. Practo also uses its own research and surveys as communication tools, as with the 2020 telemedicine report and the Practo Assured survey.
Business & Brand Outcomes
Financial trajectory. Business Today reported that revenue rose from Rs 105 crore in FY21 to Rs 240 crore in FY24, while adjusted EBITDA margin improved from -78.1% to -7.5%. According to a company statement, FY24 revenue grew 22% to Rs 240 crore, losses narrowed to Rs 17 crore from Rs 99 crore, and the first full profitable quarter came in the last quarter of FY24.
In FY25, the company reported operating EBITDA of Rs 15 crore on Rs 234 crore revenue, six consecutive profitable quarters, and contribution margin rising from 40% to 46%. Its annual letter also says gross margins in the core care-navigation business grew at a 30% CAGR over three years, and that the company moved from a Rs 162 crore loss in FY22 to a Rs 15 crore profit in FY25.
Reading these figures: reports describe the FY24 Rs 17 crore figure variously as a loss, an operating loss and an EBITDA loss, and different sources give different historical revenue bases. FY25 revenue was Rs 234 crore against Rs 240 crore the year before, so the FY25 improvement came from margins rather than reported revenue growth. Practo’s own pillars emphasise sustained profitability alongside growth.
Scale metrics. GMV was Rs 3,500 crore in FY24 and steady at the same level in FY25. Reported reach figures have changed over time. In FY24 Practo cited 150,000 doctors and 80,000 healthcare establishments. For FY25 it reported over 5 crore patients across 640 cities and over 5 lakh verified doctors, and a later Inc42 report cites over 7 lakh doctors and providers across 2,400+ cities globally. The sources do not explain how these counts are defined, so they should not be read as a like-for-like series.
Funding and valuation. The 2020 round was $32 million led by AIA with Tencent, CapitalG, Sequoia and others, reportedly valuing the company at about $310 million, roughly half its 2017 valuation, per the data aggregator cited by Global Corporate Venturing. In 2021, MCA filings reportedly showed Practo raising up to Rs 60 crore in venture debt, which the company declined to confirm.
IPO status. Bloomberg-sourced reports in December 2025 said Practo was assessing a listing in the second half of 2026. Press reports in February 2026 described advanced talks to raise $100–125 million at roughly a $700 million valuation, with a 2027 listing expected, while an April 2026 report said the company targeted $1 billion annualised GMV by June 2026 and an IPO by year-end.
Strategic Implications
Supply-side first can build a defensible position. Practo built provider relationships through software before and alongside its consumer marketplace. The documented reliance on Practo Ray for early revenue suggests that supply-side software gave the business an economic base that discovery alone did not. How that base compares with marketplace economics today is not disclosed.
Verification may matter more as listings grow. The doctor and provider counts in company communications rose sharply between FY24 and later reports, and Practo’s introductions of scores, audits and a verified network came during the same period. The two are consistent with a strategy of managing the trust risk that comes with scale, though the sources do not state this as the reason.
Growth capital and discipline pull in different directions. The documented path runs from heavy funding in 2015–2017, through a lower 2020 valuation despite pandemic demand, to profitability emphasised in FY24–FY25. The CEO’s reported FY24 revenue expectation of about Rs 400 crore against the Rs 240 crore reported shows how sharply plans moved.
International expansion is both an opportunity and an unproven test. The UAE and US launches are early and company-reported, and Insta’s UAE position rests on a company-stated share. Whether a trust-led care-navigation model transfers to regulated Western markets has no verified outcome data yet.
Discussion Questions
Practo started with provider software and added a consumer marketplace in 2013. What are the strategic advantages and risks of sequencing a two-sided platform this way, compared with building consumer demand first?
Practo has introduced scores, audits and a verified network. How should a platform balance listing growth against curation, and what trade-offs does curation create with providers?
Practo’s 2020 funding round reportedly valued the company at roughly half its 2017 valuation despite pandemic-driven demand for teleconsultation. What does this suggest about how investors value marketplaces versus durable profit pools in healthcare?
Between FY24 and FY25, reported revenue fell slightly while margins and profitability improved. Under what conditions is a margin-first strategy preferable to a growth-first one for a platform preparing to list?
Practo is expanding into the UAE and the US while competing in India with pharmacy-led, hospital-backed and AI-led platforms. Which competitive advantages travel across markets, and which are specific to India?
Comments